Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex…

Drug Manufacturers - Specialty & Generic

US, Woodcliff Lake [HQ]

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Major Shareholders · Proxy Ben. Owners

Shareholders

Major Shareholders · Structure

Breakdown

The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public. for Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc. can't present any analysts estimates at the moment detail analysis.

Intraday

Shares Outstanding

12,958,200

Volume

296

Volume on Avg.

28,581

Beneficial Owners Beta

Beneficial owners who control a significant portion of the shares outstanding.

SEC Source

Form 3/4/5

Owner	Shares	Equivalence - $0.62 per share	Last Form/Filing	Last Transaction
10% Holder
Tarriff Scott Uncategorized SEC Entity	460,621	$285,585.02	03/01/24
Tarriff Scott Internal : CEO	545,447	$338,177.14	11/03/23
Officers/Directors Below 10%
Krawtschuk Christopher Internal : Chief Financial Officer	0	$0	11/19/24	0 x $0 = $0
Cahill Brian Joseph Internal : CHIEF FINANCIAL OFFICER	25,472	$15,792.64	02/01/22	F 626 x $45.94 = $28,758.44
Graves Michael Internal : Interim Executive Chair & PEO	0	$0	03/02/22	0 x $0 = $0
Ratoff Steven B Internal : Director	0	$0	03/02/22	0 x $0 = $0
Simpson Jennifer K. Internal : Director	0	$0	03/02/22	0 x $0 = $0
Glenning Robert Internal : Director	0	$0	03/09/23	0 x $0 = $0
Edlin Richard A. Internal : Director	0	$0	03/09/23	0 x $0 = $0
Borio Luciana Internal : Director	0	$0	04/30/21	0 x $0 = $0
Moran Michael Shawn Internal : EVP, Chief Commercial Officer	22,667	$14,053.54	01/11/22	F 90 x $50.63 = $4,556.70